U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Vaccines, Blood & Biologics
  3. Science & Research (Biologics)
  4. Characterization of Bacterial Glycoconjugates and Development of Associated Vaccine Technologies
  1. Science & Research (Biologics)

Characterization of Bacterial Glycoconjugates and Development of Associated Vaccine Technologies

Principal Investigator: Willie F. Vann, PhD
Office / Division / Lab: OVRR / DBPAP / LBP

General Overview

Disease-causing bacteria coat themselves with a variety of complex chains of sugar molecules called polysaccharides. These polysaccharide coats are essential for the survival of these bacteria in the human blood stream. Since these structures are important for survival of bacteria in the blood stream they are perfect targets the body's defense mechanisms. Scientists have learned that these polysaccharide chains can be made into effective vaccines against disease causing microorganisms.

Our laboratory is studying how bacteria make these polysaccharide coats so we can develop new techniques to make vaccines against bacteria coated with these polysaccharides. Specifically, we are investigating new ways to prepare and analyze vaccines prepared from bacterial polysaccharide coats using molecular biology and biochemical techniques. What we learn from this work will be of great help to us in understanding and evaluating current and future techniques for manufacturing carbohydrate vaccines.

Scientific Overview

Bacterial pathogens are often coated with polysaccharide virulence factors and some pathogens produce toxins that bind to host oligosaccharides using those host molecules as receptors for entry into the cell. These polysaccharides and toxins are excellent targets for preventing and controlling disease. Indeed, both polysaccharides and polysaccharides conjugated to inactivated toxins are the key components of vaccines that are very effective in preventing disease caused by Haemophilus influenzae, Streptococcus pneumonia, and several serogroups (i.e., "variations of") of Neisseria meningitidis.

The goals of this research project are 1) to determine the metabolic pathway for the synthesis of polysaccharides in gram negative pathogens and use this knowledge to develop methods for preparing glycoconjugate vaccines using metabolic engineering; and 2) to improve the manufacture of current conjugate vaccines through the investigation of conjugation chemistry.

While the currently licensed polysaccharide vaccines have been successful, manufacture and control of quality and efficacy of these products present regulatory challenges due to lack of a detailed definition of the immunogens. The novel technology developed and knowledge gained by this work will help to us to better characterize vaccines and predict if alternative vaccines will be effective.

In recent years workers and manufacturers in the vaccine field have begun to employ metabolic engineering technologies to develop vaccines against the carbohydrate structures on pathogens for which no current vaccine exist. Our work in the research program described here will provide us with the necessary expertise to evaluate these new vaccines.

Publications

  1. Vaccine 2024 Oct 24;42(24):126263
    Development of a Shigella conjugate vaccine targeting Shigella flexneri 6 that is immunogenic and provides protection against virulent challenge.
    Kelly M, Janardhanan J, Wagh C, Verma S, Charles RC, Leung DT, Kamruzzaman M, Pansuriya RK, Chowdhury F, Vann WF, Kaminski RW, Khan AI, Bhuiyan TR, Qadri F, Kováč P, Xu P, Ryan ET
  2. NPJ Vaccines 2024 May 25;9(1):92
    Sustained antigen delivery improves germinal center reaction and increases antibody responses in neonatal mice.
    Lotspeich-Cole L, Parvathaneni S, Sakai J, Liu L, Takeda K, Lee RC, Akkoyunlu M
  3. Am J Trop Med Hyg 2023 Nov;109(5):1122-8
    Vaccination of rabbits with a cholera conjugate vaccine comprising O-specific polysaccharide and a recombinant fragment of tetanus toxin heavy chain induces protective immune responses against Vibrio cholerae O1.
    Kelly M, Jeon S, Yun J, Lee B, Park M, Whang Y, Lee C, Charles RC, Bhuiyan TR, Qadri F, Kamruzzaman M, Cho S, Vann WF, Xu P, Kováč P, Ganapathy R, Lynch J, Ryan ET
  4. Vaccine 2023 Jul 31;41(34):4967-77
    Development of Shigella conjugate vaccines targeting Shigella flexneri 2a and S. flexneri 3a using a simple platform-approach conjugation by squaric acid chemistry.
    Kelly M, Mandlik A, Charles RC, Verma S, Calderwood SB, Leung DT, Biswas R, Islam K, Kamruzzaman M, Chowdhury F, Khanam F, Vann WF, Khan AI, Bhuiyan TR, Qadri F, Vortherms AR, Kaminski R, Kováč P, Xu P, Ryan ET
  5. Vaccine 2021 Nov 16;39(47):6936-46
    Scalable production and immunogenicity of a cholera conjugate vaccine.
    Jeon S, Kelly M, Yun J, Lee B, Park M, Whang Y, Lee C, Halvorsen YD, Verma S, Charles RC, Harris JB, Calderwood SB, Leung DT, Bhuiyan TR, Qadri F, Kamruzzaman M, Cho S, Vann WF, Xu P, Kováč P, Ganapathy R, Lynch J, Ryan ET
  6. Biochemistry 2021 Jun 29;60(25):2044–54
    Characterization of the beta-KDO transferase KpsS, the initiating enzyme in the biosynthesis of the lipid acceptor for Escherichia coli polysialic acid.
    Lanz ND, Ming SA, Thon V, Veeramachineni VM, Azurmendi HF, Vann WF
  7. Sci Rep 2020 Jul 28;10(1):12608
    Chemical structure and genetic organization of the E. coli O6:K15 capsular polysaccharide.
    Azurmendi HF, Veeramachineni V, Freese S, Lichaa F, Freedberg DI, Vann WF
  8. Sci Rep 2020 Feb 20;10(1):3032
    Preclinical development of a fusion peptide conjugate as an HIV vaccine immunogen.
    Ou L, Kong WP, Chuang GY, Ghosh M, Gulla K, O'Dell S, Varriale J, Barefoot N, Changela A, Chao CW, Cheng C, Druz A, Kong R, McKee K, Rawi R, Sarfo EK, Schon A, Shaddeau A, Tsybovsky Y, Verardi R, Wang S, Wanninger TG, Xu K, Yang GJ, Zhang B, Zhang Y, Zhou T, The VRC Production Program, Arnold FJ, Doria-Rose NA, Lei QP, Ryan ET, Vann WF, Mascola JR, Kwong PD
  9. mSphere 2019 Oct;4(5):e00520-19
    Glycoconjugates: what it would take to master these well-known yet little-understood immunogens for vaccine development.
    Avci F, Berti F, Dull P, Hennessey J, Pavliak V, Prasad AK, Vann W, Wacker M, Marcq O
  10. Glycobiology 2018 Feb 1;28(2):100-7
    Interaction of Neisseria meningitidis Group X N-acetylglucosamine-1-phosphotransferase with its donor substrate.
    Ming SA, Cottman-Thomas E, Black NC, Chen Y, Veeramachineni V, Peterson DC, Chen X, Tedaldi LM, Wagner GK, Cai C, Linhardt RJ, Vann WF
  11. FEBS J 2017 Jun;284(11):1688-99
    In vitro generation of polysialylated cervical mucins by bacterial polysialyltransferases to counteract cytotoxicity of extracellular histones.
    Galuska SP, Galuska CE, Tharmalingam T, Zlatina K, Prem G, Husejnov FC, Rudd PM, Vann WF, Reid C, Vionnet J, Gallagher ME, Carrington FA, Hassett SL, Carrington SD
  12. Chembiochem 2017 Apr 18;18(8):799-815
    Conjugate vaccines from bacterial antigens by squaric acid chemistry: a closer look.
    Xu P, Kelly M, Vann WF, Qadri F, Ryan ET, Kovac P
  13. PLoS Negl Trop Dis 2015 Jul 8;9(7):e0003881
    A cholera conjugate vaccine containing O-specific polysaccharide (OSP) of V. cholerae O1 inaba and recombinant fragment of tetanus toxin heavy chain (OSP:rTTHc) induces serum, memory and lamina proprial responses against OSP and is protective in mice.
    Sayeed MA, Bufano MK, Xu P, Eckhoff G, Charles RC, Alam MM, Sultana T, Rashu MR, Berger A, Gonzalez-Escobedo G, Mandlik A, Bhuiyan TR, Leung DT, LaRocque RC, Harris JB, Calderwood SB, Qadri F, Vann WF, Kovac P, Ryan ET

 

Back to Top